EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan

Ichiro Mizushima, Yusuke Yoshimatsu, Hiroki Kiyohara, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Yohei Mikami, Takanori Kanai

Intestinal Research · 31.10.2026 · 24 (4) · 767-775

DOI: 10.5217/ir.2025.00176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2026. Verfasst von Ichiro Mizushima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Foundation for Applied Enzymology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Randomized controlled trials have confirmed the efficacy and safety of mirikizumab, an anti-interleukin-23p19 monoclonal antibody, for moderate-to-severe active ulcerative colitis (UC). However, there are no real-world data on the efficacy and safety of mirikizumab for UC as maintenance therapy, especially in difficult-to-treat inflammatory bowel disease (DTT-IBD). This study aimed to evaluate the long-term efficacy and safety of mirikizumab in patients with UC of DTT-IBD.

Methods

This was a single-center retrospective observational study involving adult patients with UC who received mirikizumab between January 2023 and April 2025 and met the criteria for DTT-IBD (e.g., failure of biologics and advanced small molecule drugs with at least 2 different mechanisms of action). The primary outcome was the clinical response at week 52. Secondary outcomes included steroid-free clinical remission within 52 weeks and the persistency of mirikizumab use. Adverse events were also recorded.

Results

Thirty-two patients were included in this study. The median 2-item patient-reported outcome score at baseline was 3 (interquartile range, 2–4). The proportion of patients with a clinical response at week 52 was 33.3% (95% confidence interval, 14.6%–57.0%). Steroid-free clinical remission was achieved in 26.7% (95% confidence interval, 12.3%–45.9%) of the patients. The cumulative continuous rate of mirikizumab use at week 52 was approximately 60%. Only 1 patient developed a serious adverse event requiring hospitalization (pneumonia), and mirikizumab was successfully resumed after recovery.

Conclusions

The present study demonstrated real-world data regarding maintenance therapy with mirikizumab for UC among patients with DTT-IBD.

Schlagwörter

Stichwörter der Autor:innen

Inflammatory bowel diseasesMirikizumabTreatment failureUlcerative colitis

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. yyyy1y8yyyy@keio.jp.
  • Department of Multidimensional Analysis of Gastrointestinal Biology, The Sakaguchi Laboratory, Keio University School of Medicine, Tokyo, Japan.
  • Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. takagast@keio.jp.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Foundation for Applied Enzymology

Zitieren

APA

Mizushima, I., Yoshimatsu, Y., Kiyohara, H., Sugimoto, S., Sujino, T., Takabayashi, K., Mikami, Y., & Kanai, T. (2026). Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan. Intestinal Research, 24(4), 767-775. https://doi.org/10.5217/ir.2025.00176

Vancouver

Mizushima I, Yoshimatsu Y, Kiyohara H, Sugimoto S, Sujino T, Takabayashi K, et al. Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan. Intestinal Research. 2026;24(4):767-775. doi:10.5217/ir.2025.00176

BibTeX
@article{Mizushima2026,
  author = {Mizushima, Ichiro and Yoshimatsu, Yusuke and Kiyohara, Hiroki and Sugimoto, Shinya and Sujino, Tomohisa and Takabayashi, Kaoru and Mikami, Yohei and Kanai, Takanori},
  title = {Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan},
  journal = {Intestinal Research},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {767--775},
  doi = {10.5217/ir.2025.00176}
}
Kostenlos starten →